drugset

drugset / Trial / NCT04401813

Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma

NCT04401813 ↗

Phase 1 Completed 97 enrolled Innovent Biologics (Suzhou) Co. Ltd.

NaSingle-groupOpen-labelTreatment

Summary

An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma

Timeline

Start: 2020-06-16
Primary completion: 2024-06-21
Completion: 2024-06-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sintilimab	Monoclonal antibody	200 mg	—

Indications